Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight
The chondrosarcoma market is anticipated to increase during the forecast period (2026–2036), owing to improved diagnosis, treatment advancements, increased awareness, the launch of emerging therapies such as Ozekibart (INBRX-109) (Inhibrx Biosciences), TIBSOVO (ivosidenib) (Servier), LY3410738 (Eli Lilly), and others, and global healthcare spending, reports DelveInsight.
LAS VEGAS, Feb. 26, 2026 /PRNewswire/ -- Recently published chondrosarcoma Market Insights report includes a comprehensive understanding of current treatment practices, chondrosarcoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Chondrosarcoma Market Summary
Discover chondrosarcoma treatment market trends and opportunities @ https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Chondrosarcoma Market
Aparna Thakur, Assistant Project Manager, Forecasting and Analytics at DelveInsight, noted that the chondrosarcoma treatment landscape is expected to undergo significant changes over the 2025–2034 forecast period. However, further investigation is crucial for this patient population, given the severe impact of chondrosarcoma on their quality of life and life expectancy.
Chondrosarcoma Market Analysis
Chondrosarcoma Competitive Landscape
The clinical trial landscape for chondrosarcoma is constrained. Some of the potential products in the pipeline include Ozekibart (INBRX-109) (Inhibrx Biosciences), TIBSOVO (ivosidenib) (Servier), LY3410738 (Eli Lilly), and others.
Servier's TIBSOVO is a small-molecule inhibitor that blocks the mutant IDH1 enzyme. It is approved for use in Acute Myeloid Leukemia (AML), relapsed or refractory Myelodysplastic Syndromes (MDS), and in locally advanced or metastatic cholangiocarcinoma.
A Phase III study (NCT06127407) is now underway in adults (18+) with locally advanced or metastatic conventional chondrosarcoma carrying an IDH1 mutation. Eligible participants may be either treatment-naïve or have received one previous systemic therapy. Primary completion is anticipated in February 2028.
Inhibrx Biosciences' Ozekibart (INBRX-109) is a tetravalent agonist that targets human Death Receptor 5 (DR5) to induce tumor-selective programmed cell death. Built using Inhibrx's single-domain antibody platform, it is engineered to optimize both agonistic activity and safety. DR5 is a receptor for TRAIL (Tumor Necrosis Factor–related Apoptosis-inducing Ligand). The US FDA has granted Fast Track Designation to INBRX-109 for patients with unresectable or metastatic conventional chondrosarcoma. A Phase II trial of ozekibart (NCT04950075) is currently recruiting patients with unresectable or metastatic conventional chondrosarcoma, according to ClinicalTrials.gov.
The anticipated launch of these emerging therapies are poised to transform the chondrosarcoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the chondrosarcoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about new drugs in clinical trials for chondrosarcoma @ Chondrosarcoma Drugs Market
Recent Developments in the Chondrosarcoma Market
What is Chondrosarcoma?
Chondrosarcoma is a type of cancer that develops in the cartilage, the flexible tissue that cushions joints and helps form the skeleton. It most commonly affects the bones of the pelvis, hip, and shoulder, but it can occur in any cartilage-bearing area of the body. Unlike some other bone cancers, chondrosarcoma typically grows slowly; however, certain aggressive forms can metastasize to other parts of the body. Symptoms often include persistent pain, swelling, or a noticeable lump near the affected bone. Treatment usually focuses on surgery to remove the tumor, as chondrosarcoma is often resistant to chemotherapy and radiation.
Chondrosarcoma Epidemiology Segmentation
The chondrosarcoma epidemiology section provides insights into the historical and current chondrosarcoma patient pool and forecasted trends for the leading markets. Around 75% of conventional chondrosarcoma cases in the US in 2025 were localized, while the remaining cases were metastatic.
The chondrosarcoma treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Chondrosarcoma Market Forecast Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Chondrosarcoma Epidemiology Segmentation
Total Incident Cases of Chondrosarcoma, Total Incident Cases of Primary Chondrosarcoma, Grade-specific Incident Cases of Chondrosarcoma, Mutation-specific Incident Cases of Chondrosarcoma, Stage-specific Incident Cases of Conventional Chondrosarcoma
Key Chondrosarcoma Companies
Servier, Inhibrx Biosciences (Inhibrx Biosciences), Eli Lilly (NYSE: LLY), and others
Key Chondrosarcoma Therapies
TIBSOVO, Ozekibart, LY3410738, and others
Scope of the Chondrosarcoma Market Report
Download the report to understand top companies in chondrosarcoma market @ Chondrosarcoma Market Forecast
Table of Contents
1
Chondrosarcoma Market Key Insights
2
Chondrosarcoma Market Report Introduction
3
Executive Summary
4
Key Events
5
Chondrosarcoma Market Overview at a Glance
5.1
Emerging Therapies Analysis (By Phase, RoA, and Molecule Type)
5.2
Market Share (%) Distribution of Metastatic Conventional Chondrosarcoma in 2025
5.3
Market Share (%) Distribution of Metastatic Conventional Chondrosarcoma in 2036
6
Epidemiology and Market Forecast Methodology
7
Disease Background and Overview
7.1
Introduction
7.2
Signs and Symptoms
7.3
Causes
7.4
Classification
7.5
Risk Factors
7.6
Pathophysiology of Metastatic Conventional Chondrosarcoma
7.7
Diagnosis
7.8
Treatment and Guidelines
8
Epidemiology and Patient Population of Chondrosarcoma in 7MM
8.1
Key Findings
8.2
Assumptions and Rationale: The 7MM
8.3
Total Incident Cases of Chondrosarcoma in the 7MM
8.4
The United States
8.4.1
Total Incident Cases of Chondrosarcoma in the United States
8.4.2
Total Incident Cases of Primary Chondrosarcoma in the United States
8.4.3
Grade-specific Incident Cases of Chondrosarcoma in the United States
8.4.4
Mutation-specific Incident Cases of Chondrosarcoma in the United States
8.4.5
Stage-specific Incident Cases of Chondrosarcoma in the United States
8.5
EU4 and the UK
8.6
Japan
9
Chondrosarcoma Patient Journey
10
Emerging Chondrosarcoma Therapies
10.1
Key Cross Competition
10.2
INBRX-109: Inhibrx Biosciences
10.2.1
Product Description
10.2.2
Other Developmental Activities
10.2.3.1
Clinical Trials Information
10.2.4
Safety and Efficacy
10.2.5
Analyst Views
10.3
TIBSOVO (ivosidenib): Servier
List to be continued in the report…
11
Chondrosarcoma Market: 7MM Analysis
11.1
Key Findings
11.2
Chondrosarcoma Market Outlook
11.3
Conjoint Analysis
11.4
Key Chondrosarcoma Market Forecast Assumptions
11.5
Total Market Size of Chondrosarcoma in the 7MM
11.6
Total Market Size of Chondrosarcoma by Therapies in the 7MM
11.7
The United States Chondrosarcoma Market Size
11.7.1
Total Market Size of Chondrosarcoma in the United States
11.7.2
Market size of Chondrosarcoma by Therapies in the United States
11.8
EU4 and the UK Chondrosarcoma Market Size
11.9
Japan Chondrosarcoma Market Size
12
Key Opinion Leaders' Views on Chondrosarcoma
13
Chondrosarcoma Market SWOT Analysis
14
Chondrosarcoma Market Unmet Needs
15
Chondrosarcoma Market Access and Reimbursement
15.1
The United States
15.2
In EU4 and the UK
15.3
Japan
15.4
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
16
Bibliography
17
Chondrosarcoma Market Report Methodology
Related Reports
Chondrosarcoma Clinical Trial Analysis
Chondrosarcoma Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Chondrosarcoma companies, including PharmaMar, Inhibrx, Shanghai Junshi Bioscience Co., Ltd., Hutchmed, Atlanthera, and others.
Osteosarcoma Market
Osteosarcoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key osteosarcoma companies, including Takeda Pharmaceuticals, OS Therapies, Y-mAbs Therapeutics, AlaMab Therapeutics, CSPC Pharmaceutical, MedPacto, Hansoh Pharmaceutical, Takeda, Acrotech Biopharma, Bayer, Exelixis, Nektar Therapeutics, Eisai, GlaxoSmithKline/Novartis, Aadi Bioscience, Vaccinex, Inc., National Cancer Institute/Assaf-Harofeh Medical Center, Eleison Pharmaceuticals, Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech, and others.
Soft Tissue Sarcoma Market
Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key STS companies, including Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
Ewing Sarcoma Market
Ewing Sarcoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Ewing sarcoma companies, including SALARIUS PHARMACEUTICALS, JAZZ PHARMACEUTICALS AND PHARMAMAR, ELI LILLY, PFIZER, BIOATLA, CELLECTAR BIOSCIENCES, SUMITOMO PHARMA ONCOLOGY, INHIBRX, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us :
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP